Healthcare & Pharmaceuticals

Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.
In a move activists hoped would lead to a flood of affordable AIDS medication to Africa, the pharmaceutical industry dropped its suit Thursday challenging a South African law many say would allow the government to import or produce generic versions of the drugs.
JOHANNESBURG -- A severe shortage of two antiretrovirals (ARVs) produced by leading pharmaceutical Bristol-Myers Squibb in Kenya, could have critical repercussions for patients, says Medecines sans Frontieres (MSF).
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.
When individuals sue major corporations, the odds are stacked against them. One woman's fight against an insurance giant details those odds and what it takes to beat them.
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.
The decision by PH Kurian, the controller general of patents, designs and trademarks in India, to allow a local company to manufacture Sorafenib, a drug used to treat advanced kidney cancer and liver cancer, is a welcome move that supports the access of poor people to cheap life-saving drugs.
With billions of dollars in profits on the line, the health care industry is waging the largest national advertising campaign ever conducted by a political special interest, with a price tag for the election cycle that could approach $90 million--more than either of the major presidential candidates is expected to spend.
David Franklin, the drug company whistle-blower who has sparked federal and state investigations into the marketing of the top-selling drug Neurontin, said yesterday that he and his former colleagues engaged in a series of inappropriate tactics, including misleading doctors to persuade them to prescribe the drug for unapproved uses.
The Food and Drug Administration yesterday released a warning letter it sent to the Guidant Corporation, restricting the ability of the company to win approval for some new medical products. In the letter, sent a week ago, the agency said Guidant, the heart device maker, had not fully responded to its concerns about manufacturing procedures at the company's biggest plant.